ArticleMedical cannabis and cannabinoids
Cannabinoids for Anxiety and Sleep Disturbances: A Scoping Review.
Article in Medical cannabis and cannabinoids. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Endocannabinoid system modulation in bruxism: a neurobiological hypothesis and translational model of ECS-targeted intervention.Frontiers in neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: At least 60% of individuals with anxiety disorders report sleep disturbances, which might be explained by shared physiological mechanisms, including cortisol dysregulation and executive function skills disruption. The scientific literature regarding medical cannabis as a potential therapeutic candidate for these conditions increased about 15 times in the last 10 years. However, assessments of cannabinoid exposure, anxiety, and sleep are inconsistent across studies, and the quality of the evidence is not often assessed. Summary: We conducted a scoping review to examine the current knowledge on cannabinoid use for anxiety and sleep disturbances. We applied our search strategy to PubMed, EMBASE, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, CINAHL, LILACS, and PsycINFO. Papers were selected by duplicate using PRISMA guidelines. Quality assessment was conducted for included studies, and data extraction was performed according to our predefined protocol. Of 1,132 retrieved documents, 29 studies met the inclusion criteria, encompassing randomized clinical trials, observational studies, and case series. Cannabinoids, particularly cannabidiol (CBD), showed potential efficacy in improving anxiety symptoms and sleep disturbances. However, substantial heterogeneity in study design, cannabinoid types, and dosing regimens limited generalizability. Approximately 45% of studies reported positive effects on both outcomes, yet few provided standardized dosing protocols or effect sizes. Key Messages: Cannabinoids, especially CBD, may improve anxiety and sleep disturbances, but methodological limitations and the lack of standardized dosing hinder definitive conclusions. Future research should prioritize dose-response relationships and standardized methodologies to better inform clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.